Role of protein arginine methyltransferase 5 in group 3 (MYC-driven) Medulloblastoma

[1]  Peipei Xu,et al.  PRMT5-dependent transcriptional repression of c-Myc target genes promotes gastric cancer progression , 2020, Theranostics.

[2]  I. Bahar,et al.  A novel small-molecule antagonizes PRMT5-mediated KLF4 methylation for targeted therapy , 2019, EBioMedicine.

[3]  R. Baiocchi,et al.  Protein arginine methyltransferase 5 (PRMT5) dysregulation in cancer , 2018, Oncotarget.

[4]  A. Papavassiliou,et al.  Chromatin remodeling defects in pediatric brain tumors. , 2018, Annals of translational medicine.

[5]  Jiang I. Wu,et al.  Epigenetic regulation in medulloblastoma , 2018, Molecular and Cellular Neuroscience.

[6]  M. Roussel,et al.  Epigenetic Drivers in Pediatric Medulloblastoma , 2017, The Cerebellum.

[7]  Roland Eils,et al.  The whole-genome landscape of medulloblastoma subtypes , 2017, Nature.

[8]  A. Goldenberg,et al.  Intertumoral Heterogeneity within Medulloblastoma Subgroups. , 2017, Cancer cell.

[9]  R. Baiocchi,et al.  PRMT5–PTEN molecular pathway regulates senescence and self-renewal of primary glioblastoma neurosphere cells , 2017, Oncogene.

[10]  B. Illi,et al.  Myc and Omomyc functionally associate with the Protein Arginine Methyltransferase 5 (PRMT5) in glioblastoma cells , 2015, Scientific Reports.

[11]  I. Bahar,et al.  Interplay between arginine methylation and ubiquitylation regulates KLF4-mediated genome stability and carcinogenesis , 2015, Nature Communications.

[12]  Robert A Copeland,et al.  A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models. , 2015, Nature chemical biology.

[13]  D. Shechter,et al.  The PRMT5 arginine methyltransferase: many roles in development, cancer and beyond , 2015, Cellular and Molecular Life Sciences.

[14]  Florence I. Raynaud,et al.  Combined MYC and P53 Defects Emerge at Medulloblastoma Relapse and Define Rapidly Progressive, Therapeutically Targetable Disease , 2015, Cancer cell.

[15]  J. H. Park,et al.  Protein arginine methyltransferase 5 is a key regulator of the MYCN oncoprotein in neuroblastoma cells , 2014, Molecular oncology.

[16]  Giles W. Robinson,et al.  Medulloblastoma—translating discoveries from the bench to the bedside , 2014, Nature Reviews Clinical Oncology.

[17]  H. Fathallah-Shaykh,et al.  Expression of PRMT5 correlates with malignant grade in gliomas and plays a pivotal role in tumor growth in vitro , 2014, Journal of Neuro-Oncology.

[18]  Guido Marcucci,et al.  Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma. , 2014, Cancer research.

[19]  Tao Lu,et al.  Protein arginine methylation of non-histone proteins and its role in diseases , 2013, Cell cycle.

[20]  J. Vose,et al.  Novel Treatment for Mantle Cell Lymphoma Including Therapy-Resistant Tumor by NF-κB and mTOR Dual-Targeting Approach , 2013, Molecular Cancer Therapeutics.

[21]  G. Stark,et al.  PRMT5 dimethylates R30 of the p65 subunit to activate NF-κB , 2013, Proceedings of the National Academy of Sciences.

[22]  M. Bedford,et al.  Protein arginine methyltransferases and cancer , 2012, Nature Reviews Cancer.

[23]  Steven J. M. Jones,et al.  Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma , 2013, Acta Neuropathologica.

[24]  P. Northcott,et al.  Targeting the enhancer of zeste homologue 2 in medulloblastoma , 2012, International journal of cancer.

[25]  W. Richardson,et al.  Transcription Factor Positive Regulatory Domain 4 (PRDM4) Recruits Protein Arginine Methyltransferase 5 (PRMT5) to Mediate Histone Arginine Methylation and Control Neural Stem Cell Proliferation and Differentiation* , 2012, The Journal of Biological Chemistry.

[26]  D. Kerr,et al.  Arginine methylation controls growth regulation by E2F‐1 , 2012, The EMBO journal.

[27]  P. Febbo,et al.  An animal model of MYC-driven medulloblastoma. , 2012, Cancer cell.

[28]  T. MacDonald,et al.  Medulloblastoma and primitive neuroectodermal tumors. , 2012, Handbook of clinical neurology.

[29]  Scott L. Pomeroy,et al.  Molecular subgroups of medulloblastoma: the current consensus , 2011, Acta Neuropathologica.

[30]  Yu-Jie Hu,et al.  Versatility of PRMT5-induced methylation in growth control and development. , 2011, Trends in biochemical sciences.

[31]  J. Mesirov,et al.  Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  M. Surani,et al.  Prmt5 is essential for early mouse development and acts in the cytoplasm to maintain ES cell pluripotency. , 2010, Genes & development.

[33]  M. Jansson,et al.  Arginine methylation regulates the p53 response , 2008, Nature Cell Biology.

[34]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..